When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MYOK - Early-stage study underway for MyoKardia's MYK-224
MyoKardia Inc.
The first participants have been dosed in a Phase 1 clinical trial evaluating MyoKardia's (MYOK+0.5%) MYK-224 for the treatment of hypertrophic cardiomyopathy (HCM), a common heart condition in which the cardiac muscle cells enlarge causing the walls of the ventricles to thicken compromising the ability of the heart to pump blood. It can cause cardiac arrest in young people (instances involving athletes routinely appear in the press).
More news on: MyoKardia, Inc., Healthcare stocks news,